Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | CCKBR | P32239 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3964364 | 1.00 | EGFR (0.47) | EGFRCCKBRTP53L3MBTL1GLA | |
| SCHEMBL3958089 | 1.00 | EGFR (0.47) | EGFRCCKBRTP53L3MBTL1GLA | |
| SCHEMBL9910178 | 0.87 | CCKBR (0.42) | EGFRCCKBRALDH1A1 | |
| SCHEMBL13298503 | 0.85 | MTNR1A (0.41) | EGFRCCKBR | |
| SCHEMBL5635451 | 0.85 | HSD17B10 (0.43) | EGFRCCKBRHSD17B10ALDH1A1 | |
| SCHEMBL17072375 | 0.84 | CCKBR (0.41) | EGFRCCKBRALDH1A1 | |
| SCHEMBL6890519 | 0.83 | EGFR (0.50) | EGFRCCKBR | |
| SCHEMBL8367985 | 0.83 | EGFR (0.45) | EGFRCCKBRTP53L3MBTL1GLA | |
| SCHEMBL10820393 | 0.82 | CCKBR (0.39) | CCKBR | |
| SCHEMBL28369724 | 0.82 | SMN1; SMN2 (0.50) | TP53HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116794202-A | Screening and application of metabolic markers of rifampicin drug-resistant tuberculosis | 首都医科大学附属北京胸科医院 | 2023-09-22 | — | — | CN | disclosed |
| CN-103044310-B | Indoline-3-acetic acid derivative and preparation method thereof as well as application of derivative in medicine | UNIV GUIYANG MEDICAL | 2015-02-04 | — | — | CN | disclosed |
| CN-103044310-B | Indoline-3-acetic acid derivative and preparation method thereof as well as application of derivative in medicine | UNIV GUIYANG MEDICAL | 2015-02-04 | — | — | CN | disclosed |
| CN-103044310-A | Indoline-3-acetic acid derivative and preparation method thereof as well as application of derivative in medicine | UNIV GUIYANG MEDICAL | 2013-04-17 | — | — | CN | disclosed |
| CN-103044310-A | Indoline-3-acetic acid derivative and preparation method thereof as well as application of derivative in medicine | UNIV GUIYANG MEDICAL | 2013-04-17 | — | — | CN | disclosed |
| US-20120101164-A1 | ABSCISSION AND CROP STORAGE UNIT | TAMINCO, NAAMLOZE VENNOOTSCHAP (BE) | 2012-04-26 | — | — | US | disclosed |
| WO-2012020567-A1 | ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-02-16 | — | — | WO | disclosed |
| CN-101687789-A | Novel inhibitors hepatitis c virus replication | INTERMUNE INC | 2010-03-31 | — | — | CN | disclosed |
| EP-2134683-A2 | NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION | Intermune, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2009126782-A1 | HISTAMINE H3 RECEPTOR LIGANDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-15 | — | — | WO | disclosed |
| US-7544685-B2 | 2,3-dihydroindole compounds | H. LUNDBECK A/S (DK) | 2009-06-09 | — | — | US | disclosed |
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2008109179-A1 | METALLOPROTEASE INHIBITORS CONTAINING A SQUARAMIDE MOIETY | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008100867-A2 | NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| US-20070043058-A1 | Novel 2,3-dihydroindole compounds | H. LUNDBECK A/S (DK) | 2007-02-22 | — | — | US | disclosed |
| US-6043257-A | ANTICOAGULANT; PYRIDINE SUBSTITUTED INDAZOLE COMPOUND | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-03-28 | — | — | US | disclosed |
| EP-0960102-A1 | AMIDINOINDOLES, AMIDINOAZOLES, AND ANALOGS THEREOF AS INHIBITORS OF FACTOR Xa AND OF THROMBIN | Du Pont Pharmaceuticals Company (US) | 1999-12-01 | — | — | EP | disclosed |
| US-5886191-A | ANTICOAGULANTS | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-03-23 | — | — | US | disclosed |
| WO-1998001428-A1 | AMIDINOINDOLES, AMIDINOAZOLES, AND ANALOGS THEREOF AS INHIBITORS OF FACTOR Xa AND OF THROMBIN | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043058-A1 | Novel 2,3-dihydroindole compounds | HTR2C, HTR2A, HTR5A | EGFR 2385/4885CCKBR 162/4885TP53 4563/4885 |
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | EGFR 913/4885CCKBR 1135/4885TP53 611/4885 |
| US-20120101164-A1 | ABSCISSION AND CROP STORAGE UNIT | BROX, ACR, ABAT | EGFR 4831/4885CCKBR 3955/4885TP53 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.